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Summary: Microglia, the resident innate immune cells in the
brain, have long been implicated in the pathology of neurode-
generative diseases. Accumulating evidence points to activated
microglia as a chronic source of multiple neurotoxic factors,
including tumor necrosis factor-, nitric oxide, interleukin-1,
and reactive oxygen species (ROS), driving progressive neuron
damage. Microglia can become chronically activated by either
a single stimulus (e.g., lipopolysaccharide or neuron damage)
or multiple stimuli exposures to result in cumulative neuronal
loss with time. Although the mechanisms driving these phe-
nomena are just beginning to be understood, reactive micro-
gliosis (the microglial response to neuron damage) and ROS
have been implicated as key mechanisms of chronic and neu-
rotoxic microglial activation, particularly in the case of Parkin-
son’s disease. We review the mechanisms of neurotoxicity
associated with chronic microglial activation and discuss the
role of neuronal death and microglial ROS driving the chronic
and toxic microglial phenotype. Key Words: Microglia, in-
ﬂammation-mediated neurodegeneration, oxidative stress,
chronic neurotoxicity, reactive microgliosis.
INTRODUCTION
Neurodegenerative diseases (e.g., Alzheimer’s dis-
ease, Parkinson’s disease (PD), Huntington’s disease,
amyotrophic lateral sclerosis, and so forth) share many
common characteristics, such as changes in microglial
number and morphlogy, elevated cytokine levels, oxida-
tive stress, and progressive neuronal loss. Increasing ev-
idence reports that microglia can become a chronic
source of cytokines and reactive oxygen species (ROS)
to drive progressive neuron damage, and it is implicated
in the chronic nature of neurodegenerative diseases.1
Although we are predominantly focusing on PD in this
article, we also discuss the mechanisms through which
microglia can become neurotoxic, we explain current
views on why the microglial response is chronic, and we
discuss the meaning of these ﬁndings in respect to the
progressive nature of neurodegenerative disease.
MICROGLIAL ORIGIN AND MAINTENANCE
IN THE CNS
Microglia reside in the CNS, comprise approximately
12% of the brain2 (depending on brain region, health, or
pathology), and serve as the brain’s immune defense.
Microglia are unique from neurons, oligodendrocytes,
and astrocytes, in that they are not derived from the
neuroectoderm. Instead, it is generally accepted that the
original microglial population in the CNS differentiates
from the cells of the myeloid lineage that originate in
bone marrow,2 which occurs early in embryonic devel-
opment.3 These myeloid cells can be found within the
CNS by embryonic day 8 in rodents,4 and by week 12 of
gestation in humans.5 At this stage, the cells are referred
to as fetal macrophages, and these are the earliest form of
microglial precursor cells present in the embryonic CNS.
Once fetal macrophages reside in the developing CNS,
they begin the differentiation process that will result in
the formation of fully-matured microglia. Although the
course of this differentiation is not fully understood, one
of the early steps is the formation of rounded “ameboid”
microglia that cluster within distinct anatomical regions
in the developing brain and may act as a source of
microglial progenitors.6 Later in embryonic and early
fetal development, these progenitors will follow a path of
migration and differentiation leading to the mature mi-
croglia, a process that extends into neonatal develop-
ment. Differentiation ﬁrst involves the formation of par-
Address correspondence and reprint requests to: Michelle L. Block,
Ph.D., Department of Anatomy and Neurobiology, Sanger Hall, Room
9-048, 1101 E. Marshall St., Virginia Commonwealth University Med-
ical Campus, Box 980709, Richmond, VA 23298-0709. E-mail:
mblock@vcu.edu.
Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics
Vol. 7, 354–365, October 2010 © The American Society for Experimental NeuroTherapeutics, Inc.354
tially ramiﬁed microglia followed by the development of
fully ramiﬁed, or branched, microglia that express cell
surface molecules characteristic of resting microglia
(discussed as follows).7
Although the origin of initial microglia populations
within the CNS has been well supported, the replacement
of microglial populations is matter of more debate. Due
to the presence of the blood brain barrier, it was origi-
nally perceived that the circulating immune cells did not
have immediate access to the CNS, keeping populations
of microglia distinct from similar, circulating blood cells.
However, there is increasing evidence that bone-marrow
derived cells are capable of entering the CNS and dif-
ferentiating into microglia in adults.8 For example, stud-
ies using bone marrow-chimeras have shown that circu-
lating monocytes inﬁltrate the CNS under different
conditions of injury, inﬂammation, or disease.9–11 This
has been shown to be possible even when the blood brain
barrier remains intact, suggesting a mechanism for entry
into the CNS.9 A possible mechanism for this could be
replenishment from perivascular cells, which are bone
marrow-derived and have been shown to enter the CNS
and differentiate into microglia.12,13 The mechanisms
through which circulating cells are recruited to the CNS,
and whether they enter the CNS under normal, resting
conditions, however, are poorly understood. At present,
there is also ongoing debate regarding the function of
inﬁltrating cells versus resident microglia for which it
has been suggested that inﬁltrating precursor cells may
be predominantly beneﬁcial cellular actors of wound
healing14 and an underutilized therapeutic resource.8
What also remains unclear is whether microglia are
capable of a level of self-renewal that is sufﬁcient to
support the population of microglia in both resting and
activated states. Microglia have a low mitotic rate when
at rest, but are capable of high rates of proliferation when
activated, suggesting that they have at least a par-
tial ability to counteract cell turnover.15,16 In addition,
populations of microglial progenitors have been pro-
posed to persist in the adult brain that are capable of pro-
liferating to replace microglial populations.4,17 At
present, we are just beginning to understand these basic
principles regarding the origin and replacement of mi-
croglia, and further research is needed to fully elucidate
the mechanisms involved in the complicated life cycle of
the immune system of the CNS.
MICROGLIAL ACTIVATION AND FUNCTION
Resting microglia
Analogous to the role of macrophages and lympho-
cytes in the periphery, one role of microglia is to act as
the brain’s immune defense against disease and injury. In
addition to these duties, however, microglia are involved
in a number of processes in the normal, healthy CNS. In
a normal brain, microglia are said to be resting, and can
be distinguished by both their morphology and pattern of
gene expression. In this state, microglia take on a rami-
ﬁed appearance, in which long, thin processes extend
from the cell body into the surrounding milieu. The
immunological phenotype of this state is characterized
by low expression of major histocompatability complex
(MHC) proteins and other antigen-presenting surface re-
ceptors.18 This phenotype is in stark contrast to that of
other macrophages, which exist in a more readily acti-
vated state. One of the reasons for this may be the ab-
sence of serum proteins in the brain that have been
shown to cause macrophage activation.19 In addition, the
expression of certain receptors, such as CD200 and
CX3CR1 on the microglia cell surface, may interact with
ligands that keep microglia in a resting state.20,21 Rest-
ing, ramiﬁed, microglia cell bodies are spaced through-
out the CNS to avoid cell body overlap, but have been
shown to be present with variable density in different
brain regions.22 Notably, this ramiﬁed morphology oc-
curs only in vivo and is relatively absent from microglia
in cell cultures.
Despite the fact that these ramiﬁed microglia are re-
ferred to as resting, they are constantly surveying the
surrounding environment by extending and retracting
their processes.23,24 In doing this, microglia are able to
sample the microenvironment, maintain homeostasis,
and identify signals that require a response. When react-
ing to extracellular signals, such as the presence of
pathogens, foreign material, and dead or dying cells,
microglia may undergo a morphological change into an
ameboid shape with short or nonexistent processes.25
This morphological change is also accompanied by
changes in signaling and gene expression that can result
in changes in surface receptor expression, the release of
pro- or anti-inﬂammatory factors, recruitment molecules,
and ROS, among others.26–29 The cumulative effect of
these changes in morphology and phenotype is a shift
from resting to activated microglia.
Microglial activation and function in the healthy
CNS
Microglia are activated in response to brain injuries
and immunological stimuli25,30–32 to undergo dramatic
alterations in morphology, changing from resting, rami-
ﬁed microglia into activated, amoeboid microglia,25
which is believed to favor phagocytosis and mobility.
Unfortunately, changes in morphology are unlikely to
differentiate between benign and toxic microglial activa-
tion.33
In nonpathological states, microglia respond to extra-
cellular stimuli in a number of ways. In the developing
brain, and in areas of remodeling, microglia are respon-
sible for the phagocytosis of cellular debris resulting
from apoptosis and normal cell death.18 Microglia are
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also responsible for the phagocytosis of other debris
present in the extracellular space, including damaged
cells, plaques, and foreign matter. For microglia sur-
rounding neurons, subtypes of microglia can provide
trophic support to neurons through the release of nerve
growth factors, neurotrophins, and other neurotrophic
factors.34 These microglia are also capable of assisting in
synaptic plasticity, an observation that was ﬁrst made in
the mid-20th century.35 Along these lines, microglia
have been implicated as the “brain’s electricians,”36 in
which the release of neurotrophic factors and anti-in-
ﬂammatory cytokines from microglia has been shown to
promote synaptic plasticity.37–39 Speciﬁcally in response
to injury, activated microglia have been shown to sur-
round damaged neurons and participate in synaptic strip-
ping, a process of removing branches from damaged
neurons to promote repair and regrowth,35,40,41 although
recent evidence shows that microglia may play an indi-
rect, anti-inﬂammatory role in this process.42 Notably,
these beneﬁcial microglial functions often involve
changes resembling an activated morphology and protein
expression, yet the function is distinct from a classic
pro-inﬂammatory response.
In fact, the majority of microglial functions are bene-
ﬁcial and necessary for a healthy CNS, as activated mi-
croglia are critical for CNS wound healing.36 For exam-
ple, ablation of inﬁltrating bone marrow derived cells
(that become microglia) in spinal cord injury at speciﬁc
times has been shown to have disastrous neurotoxic con-
sequences.14 In addition, microglia have also been shown
to release anti-inﬂammatory and trophic molecules to
enhance the survival of surrounding neurons.43,44 Thus,
evidence supports that when microglia become neuro-
toxic, this is due to both the loss of the beneﬁcial func-
tions36 and/or a shift to a pro-inﬂammatory pheno-
type.1,45,46
Pro-inﬂammatory microglial activation
Microglia detect and respond to pro-inﬂammatory trig-
gers by changing to an activated phenotype, resulting in
a shift of cellular function to releasing cytotoxic factors
(e.g., tumor necrosis factor- [TNF-], NO, and ROS)
aimed at destroying the invading pathogens. Surface
molecules associated with the innate immune response,
such as complement receptors and MHC molecules, are
also upregulated upon microglial activation.47,48 For ex-
ample, upregulation of MHC proteins enable microglia
to act as antigen-presenting cells to T-cells that will enter
the brain during active infections.18
Microglia are readily activated by an extensive list of
pro-inﬂammatory stimuli, such as lipopolysaccharide
(LPS),49–51 pesticides (e.g., paraquat,52 dieldrin,53,54 lin-
dane,54 and rotenone55), disease proteins (e.g., beta-amy-
loid peptide [A],56  synuclein,57 and human immuno-
deﬁciency virus (HIV)-Tat58), air pollution,59 and even
neuron damage.46 In fact, it has been proposed that many
disease proteins and environmental toxicants trigger a
toxic microglial response because they are misinter-
preted as a pathogen.1 In response to these triggers, mi-
croglia can produce of a large array of cytotoxic factors,
such as superoxide (O2●),27 nitric oxide (NO),60,61 tu-
mor necrosis factor-alpha (TNF-),62,63 and inﬂamma-
tory prostaglandins.64 Although the detailed components
of the microglial response can be stimulus speciﬁc, there
are common factors of microglial activation.46
LPS is a cell wall component of gram-negative bacte-
ria and is a potent stimulus of the microglial innate
immune response. The microglial response to LPS has
been well-characterized and provides excellent insight
into the timing of the multiple factors produced in a
pro-inﬂammatory response. Notably, extracellular O2●
is an immediate toxic factor released by microglia in
response to LPS. Interestingly, unique to microglia, LPS-
induced production of O2● is not mediated through the
traditional LPS receptor, the toll-like 4 receptor.50 In
fact, recent work has indicated that the MAC-1 receptor
is responsible for the LPS-induced activation of nicotin-
amide adenine dinucleotide phosphate (NADPH) oxi-
dase and the consequent production of O2● in micro-
glia.49 Thus, the microglial (O2●) response is typical
(although less robust) when compared with other profes-
sional phagocytes, but the mechanisms mediating this
response may be cell-speciﬁc.
Although the microglial superoxide response is imme-
diate, microglia also respond to LPS with a later pulse of
pro-inﬂammatory factors, such as TNF-, IL-1, and
NO, both in vivo and in vitro.65 Speciﬁcally, there is a
delay in the production of TNF-, NO, prostaglandin E2
(PGE2), and interleukin (IL)-1, in which the TNF-
peaks at 6 hours, the NO peaks at 12 hours, and both the
PGE2 and the IL-1 peak at approximately 24 hours.65
Thus, one mechanism through which microglia are be-
lieved to cause neuron damage is through the excessive
and inappropriate release of toxic factors.
Microglia in disease
Neuroinﬂammation is characteristic of many neurode-
generative diseases and microglia have been implicated
to play both causative and exacerbating roles. In fact,
microglia and inﬂammation-mediated neurodegeneration
has been implicated in numerous other diseases and con-
ditions, such as hypoxia,66 stroke,67 and neuropathic
pain.68 Neurodegenerative diseases are characterized by
chronic and progressive neuronal loss, and pathological
levels of cytotoxic substances, such as extracellular de-
bris, elevated levels of pro-inﬂammatory factors, and
production of reactive oxygen species, resulting in oxi-
dative stress. These factors, in addition to the release of
others that can activate and recruit microglia, support a
role for microglia in diseases, such as Alzheimer’s dis-
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ease,69 PD,69 multiple sclerosis,70 amyotrophic lateral
sclerosis,71,72 and HIV-associated neurocognitive disor-
der.73
Although microglia undergo changes as a result of
normal aging, including increases in activation or de-
creases in function and proliferation,74 the activation of
microglia in age-dependent neurodegenerative diseases,
such as Alzheimer’s disease and PD, seem to be a dis-
tinct process.75 One of the hallmarks of Alzheimer’s
disease pathology is the existence of -amyloid plaques,
an extracellular protein aggregate, which is normally
cleared by microglia. Activated microglia and their toxic
effects have been associated with Alzheimer’s disease
for decades.76–78 This has led to research showing that
not only is -amyloid directly toxic to neurons,79 but it
also causes microglia to cluster around plaques and be-
come activated, which may perpetuate neuronal damage
and death.80,81 Similarly, activated microglia are associ-
ated with damaged neurons in patients with PD,69 which
is discussed in more detail as follows.
In contrast to diseases speciﬁcally associated with ag-
ing, microglial activation can also play a role in diseases
not related to age, and may involve unique properties of
microglial cells. A strong example of this is in multiple
sclerosis, a disease associated with severe inﬂammation
and demyelination of axons. Usually considered an au-
toimmune disease, multiple sclerosis is associated with
lesions within the white and gray matter of the CNS that
have increased levels of activated microglia.82,83 In ad-
dition to increases in microglia-released ROS and pro-
inﬂammatory cytokines,84–86 microglia may play a large
part in the initiation of disease by acting as antigen-
presenting cells targeting myelin.87 In HIV-associated
neurocognitive disorder, microglia play a strong part
in harboring the HIV and acting as a site of viral
replication.88,89 During this process, microglia become
activated and release pro-inﬂammatory cytokines.90 In
addition, microglia are activated by HIV proteins,
such as Tat,91 to produce ROS. Thus, the interaction
between microglia, viral replication/proteins, and the
production of cytotoxic factors in HIV-associated neu-
rocognitive disorder has strong implications for dis-
ease progression.
These neurodegenerative diseases, as well as others,
such as amyotrophic lateral sclerosis, Huntington’s dis-
ease, and prion diseases, highlight the role that activated
microglia can play in cell damage and death. However,
in cases of these pathologies, the exact role of microglia
remains controversial. Ongoing research seeks to answer
questions pertaining to microglial activation in both the
development and progression of neurodegeneration.
Microglia activation and PD
In contrast to the beneﬁcial housekeeping duties of
resting and moderately activated microglia, over-activa-
tion of microglia resulting in excess production of in-
ﬂammatory mediators is in fact neurotoxic,92–94 and mi-
croglial activation has been strongly linked to pathology
in PD.1,95 The term over-activation describes the state in
which microglia continually produce inﬂammatory me-
diators, which accumulate to levels that are harmful to
neurons,96–98 and often in combination leads to neuro-
degeneration.94,98,99
Pioneering work by McGeer et al.69 discovered in-
creased staining of the MHC class II cell surface receptor
HLA-DR in the substantia nigra (SN) of postmortem PD
patient brains, indicating the presence of activated mi-
croglia, and ﬁrst implicating that these cells may have an
active pathological role in disease. Since then, many
inﬂammatory mediators such as TNF-, IL-1, and IL-6
have been identiﬁed in the striatum in human PD post-
mortem brains,100–104 in addition to an upregulation of
inducible nitric oxide synthase (iNOS) and cyclo-oxy-
genase 2 in ameboid microglia located in the SN of PD
patients,105 further suggesting a link between activated
microglial cells and neuronal damage in disease. Re-
search has identiﬁed a critical role for neuroinﬂammation
in dopamine (DA) neuron damage, as cytokines such as
TNF-106–108 have been shown to exert DA neuron dam-
age. In fact, continuous expression of low levels of
TNF- in the SN induced by an adenoviral vector will
cause chronic microglia/macrophage activation, progres-
sive neurodegeneration, and delayed motor symp-
toms.109 Thus, it is not surprising that anti-inﬂammatory
approaches,95,110–112 including those focusing on TNF-
,99,113,114 have been targeted as therapeutic strategies.
Subsequent studies provide a wealth of evidence con-
ﬁrming the presence of activated microglia in PD and
PD-like brains. For instance, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) is an illicit drug contaminant
linked to human Parkinsonism cases,115 which is com-
monly used as an animal model of PD.116 After MPTP
administration, microglial activation in the SN of mouse
brain has been conﬁrmed by an increase in cell number,
changed cell morphology, increased lectin staining,
larger cell bodies, and thicker processes.117,118 Activated
microglia are also present in the brains ofMPTP intoxicated
monkeys.119,120 Using positron emission tomographic im-
aging, a 6-hydroxydomapine model of DA neuron damage
showed decreased binding of C-PK11195 in the striatum,
indicating increased activation of microglia.121 Importantly,
these ﬁndings parallel what is seen in the human PD post-
mortem brain.100,122,123 More recently, positron emission
tomographic imaging has shown that over-activated micro-
glia are also present in the SN of living PD patients and are
associated with DA neuron damage.124,125 Thus, evidence
strongly supports that microglia may play a role in the
active pathology driving PD.
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MICROGLIA-MEDIATED DOPAMINERGIC
NEURON DAMAGE
Several studies using animal models have demon-
strated that the presence of microglia and the production
of neurotoxic factors can initiate and amplify neuron
damage. Interestingly, multiple factors and toxins are
shown to selectively damage DA neurons through mi-
croglial activation, such as rotenone,126 diesel exhaust
particles,127 paraquat,52 -synuclein,57 and A.128 How-
ever, early studies using the immunogen LPS, demon-
strate that a pro-inﬂammatory trigger, such as LPS, is
toxic to DA neurons only in the presence of micro-
glia,127,129,130 whereas LPS was one of the ﬁrst micro-
glia-mediated selective DA toxins identiﬁed. At present,
it is unclear why DA neurons are more vulnerable to
microglial activation when compared with other cells
types, but inherent vulnerability to oxidative stress has
been implicated.1
MICROGLIAL NADPH OXIDASE, ROS, AND
NEUROTOXICITY
Redox signaling
Unregulated, excessive ROS can indiscriminately
damage biomolecules (e.g., protein carbonyls) to impair
cellular function, a mechanism through which ROS is
believed to contribute to neurodegenerative disease.131
However, in addition to permanent damage, ROS is ca-
pable of a more elegant and selective modiﬁcation of
proteins, whereas ROS is known to target thiol functional
groups on cysteine amino acid residues.131 These revers-
ible modiﬁcations can be likened to phosphorylation, and
they can regulate protein function, acting as an important
process of signal transduction in multiple cell types,
including microglia.
Microglial ROS production and NADPH oxidase
The production of ROS in phagocytes is derived from
multiple sources, such as peroxidases inside the cell,
NADPH oxidase on the membrane surface, or the oxi-
dative processes of mitochondria.132 NADPH oxidase is
a multi-subunit enzyme that catalyzes the production of
O2● from molecular oxygen, and it is the predominant
source of extracellular ROS in phagocytes, such as mi-
croglia.129,130 The enzyme complex is dormant in resting
phagocytes and can be activated on exposure to speciﬁc
stimuli, such as bacteria and inﬂammatory peptides.133 In
resting cells, the cytosolic subunits of NADPH oxidase
(p47, p67, p40, and Rac2) are distributed between the
cytosol and the membranes of intracellular vesicles and
organelles.133 However, activation induces the cytosolic
subunits to translocate to the membranes, where they
bind to the membrane-associated subunits (p22 and
gp91), assembling the active oxidase that produces
O2●.133
NADPH oxidase and intracellular ROS have been im-
plicated in several cellular functions, such as migra-
tion134 and phagocytosis.135 Speciﬁc to microglia, ROS
produced from NADPH oxidase has been shown to me-
diate changes in microglia morphology,130 pro-inﬂam-
matory gene expression,130 and upregulation of markers
in response to immunological stimuli.136
Interestingly, NADPH oxidase is upregulated in neu-
rodegenerative diseases, such as PD137 and Alzheimer’s
disease,138 indicating a potential role for microglial
NADPH oxidase activation in disease and neuron death.
In fact, the critical role of NADPH oxidase in mediating
inﬂammation-related neurotoxicity has been well docu-
mented,130 whereas the LPS-induced loss of nigral DA
neurons in vivo and in vitro was signiﬁcantly less pro-
nounced in NADPH oxidase-deﬁcient mice, when com-
pared with control mice. NADPH oxidase has also been
linked to microglia-derived oxidative stress from a vari-
ety of neurotoxic insults, such as rotenone,126 diesel ex-
haust particles,127 -synuclein,57 A,128 paraquat,139
dieldrin,54 DA neuronal injury,137,140 prothrombin krin-
gle-2,141 2 adrenergic-receptor activation,142 angioten-
sin,143 and cerebral ischemia-reperfusion injury,144,145
indicating that microglial NADPH oxidase activation
may also be a common denominator of microglial acti-
vation associated with neurotoxicity. Currently, the pre-
cise species of ROS responsible for NADPH oxidase-
induced neurotoxicity are unknown. However, SOD and
catalase mimetics, which remove O2● and hydrogen
peroxide (H2O2), respectively, reduce LPS-induced DA
toxicity,146 indicating the critical importance of H2O2
and O2● in microglia-mediated neurotoxicity. Thus, mi-
croglial-derived ROS may be an essential and common
factor of toxic microglial activation.
NADPH oxidase and redox signaling
The phagocytic oxidase-ROS signaling pathway is the
signaling mechanism induced by the increase in intracel-
lular ROS in phagocytes as a response to NADPH oxi-
dase activation (pro-inﬂammatory redox signaling in
phaogocytes). The increase in intracellular ROS in
phagocytes, such as microglia, includes a number of ox-
ygen species, such as O2●, hydroxyl radical (OH●,
lipid hydroperoxides, and their byproducts (e.g.,
H2O2).147 Although multiple cellular organelles and en-
zymes contribute to intracellular ROS, it is not surprising
that the amount of intracellular ROS produced by
NADPH oxidase is dependent on the stimuli. For exam-
ple, NADPH oxidase contributes to approximately 50%
of the LPS-induced intracellular ROS increase130 in mi-
croglia, but substance P-induced intracellular ROS is
nearly completely dependent on NADPH oxidase.148 In
the traditional phagocyte, the phagocytic oxidase-ROS
pathway has been shown to amplify pro-inﬂammatory
gene expression through their function as second mes-
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sengers to regulate several downstream signaling mole-
cules, including protein kinase C, mitogen activated pro-
tein kinase, and nuclear factor-B,135,149–151 through
redox signaling.
Using neuron-glia cultures from NADPH oxidase-de-
ﬁcient mice, studies have shown that NADPH oxidase
initiates an intracellular ROS signaling pathway152 that
can activate microglia and amplify the production of
pro-inﬂammatory cytokines, such as TNF-130 or
PGE2.153 In addition, Min et al.154 demonstrated that
ganglioside induces the activation of microglia, whereas
the production of IL-1, TNF-, and iNOS are attenu-
ated by the addition of the NADPH oxidase inhibitor,
diphenylene iodonium. Furthermore, NADPH oxidase
inhibitors and catalase are shown to suppress LPS-in-
duced expression of cytokines (IL-1, IL-6, and TNF-),
iNOS, mitogen activated protein kinase, and nuclear fac-
tor-B phosphorylation.155 Thus, both microglial cellular
function and signaling pathways are modiﬁed by
NADPH oxidase ROS production.
Accumulating evidence supports that NADPH oxidase
contributes to microglia-mediated neurotoxicity through
two mechanisms. First, activation of NADPH oxidase
results in the production of extracellular ROS that is
toxic to neurons. Second, activation of NADPH oxidase
causes an increase in the microglial intracellular ROS,
which enhances the production of pro-inﬂammatory fac-
tors that are toxic to neurons. Given the dual impact of
NADPH oxidase activation on neurotoxicity, the role of
NADPH oxidase in generating toxic ROS, and the prev-
alence of NADPH oxidase activation on microglial acti-
vation, suggests that microglial NADPH oxidase is a
critical mechanism of neuronal death across multiple
neurodegenerative diseases. However, the speciﬁc mech-
anisms deﬁning how ROS causes this toxic microglial
phenotype through redox-signaling is unknown.
CHRONIC MICROGLIAL
ACTIVATION—PROPAGATION OF DISEASE
Microglia are unique when compared with differen-
tiated myeloid immune cells in the periphery for mul-
tiple reasons. In addition to the obvious morphological
differences and unique resting proﬁles characterized in
microglia, these cells are also more likely to establish
chronic pro-inﬂammatory responses, rather than dem-
onstrate resolution of the innate immune response, as
is common in the peripheral immune system.156 Al-
though the mechanisms are unclear, we believe that
this microglial tendency for a chronic pro-inﬂamma-
tory response is a key factor driving progressive neu-
ron damage, contributing to the chronic nature of neu-
rodegenerative diseases.
Reactive microgliosis-chronic response to a single
stimulus
Although microglial activation was initially perceived
as a transient event,31 it is now believed to be chronic and
culpable in the propagation of disease.1,94,157 Reports
have shown that microglia can remain chronically acti-
vated140,158,159 in a process that has been termed reactive
microgliosis. Reactive microgliosis can be deﬁned as
microglial activation, which occurs in response to neu-
ronal damage, which is then perpetuated by further mi-
croglial activation and neurotoxicity (FIG. 1). Thus, a
self-propelling and progressive cycle of microglial acti-
vation and neuron damage ensues.1
For example, to damage DA neurons, MPTP is metab-
olized to 1-methyl-4-phenylpyridinium (MPP), which
is then selectively taken up by the dopamine transporter,
resulting in inhibition of the mitochondrial electron
transport chain complex I.160 In addition to this mecha-
nism of direct neurotoxicity, MPTP-induced neurotoxic-
ity is also clearly linked with microglial activation in
vivo and in vitro.137,140,159
It is particularly interesting that chronic microglial
activation can continue years after MPTP exposure in
humans122 and primates,159 despite the fact that the ex-
posure to MPTP was brief, indicating an incessant, active
pathologic process. Importantly, several studies have
shown that microglia have an active role in the process of
neuronal death in MPTP/MPP-induced neurotoxici-
ty.137,140,159 Speciﬁcally, in vitro studies show that while
MPTP directly damages DA neurons, both MPTP and
MPP fail to directly activate microglia.140 Rather, mi-
croglial activation in response to MPTP or MPP occurs
only when neurons are present and this response takes
time (days) to accumulate.140 Furthermore, the addition
of microglia to enriched neuron cultures greatly en-
hances MPTP-induced DA toxicity,140 demonstrating
that microglia cause DA neuron damage in addition to
the direct toxic effects of MPTP/MPP on the neuron.
In vivo studies also emphasize the important role of
inﬂammation as a toxic component of MPTP/MPP neu-
rotoxicity,161 in which DA neuron damage in response to
MPTP is signiﬁcantly reduced in mutant mice with de-
ﬁcient production of pro-inﬂammatory factors, such as
nitric oxide,162 superoxide,137,163 prostaglandins,164,165
and TNF-.108 Thus, several lines of evidence suggest
that microglial activation initiated by neuronal damage
may be toxic and persistent, continuing long after the
initiating damaging/toxic stimulus is gone.
Recently, we used an in vitro approach to separate
neuron injury factors from the cellular actors of reactive
microgliosis in an attempt to begin to discover molecular
signals (soluble neuron injury factors) responsible for
chronic and toxic microglial activation.166 We found that
when injury with the DA neurotoxin MPP occurred,
DA neurons released soluble neuron injury factors that
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activated microglia and were selectively toxic to DA
neurons in mixed mesencephalic neuron-glia cultures
through NADPH oxidase.166 This is consistent with other
studies that have identiﬁed other soluble neuron injury
factors that signal toxic microglial activation, such as
matrix metalloproteinase 3,167  synuclein,57 and neu-
romelanin.168 In addition, we identiﬁed  calpain as a
key soluble neuron-injury signal released from damaged
neurons, causing selective DA neuron death through ac-
tivation of microglial NADPH oxidase and superoxide
production, converging on the common mechanism of
toxic microglial activation through ROS production.166
Together, these ﬁndings support that DA neurons may be
inherently susceptible to reactive microgliosis, providing
much needed insight into the chronic nature of PD. No-
tably, although DA neurons may be more vulnerable to
reactive microgliosis, it is likely that reactive microglio-
sis is a contributing factor to most neurodegenerative
diseases.
LPS-chronic response to a single stimulus
LPS is reported to activate microglia both in vivo and
in vitro causing the progressive and cumulative loss of
DA neurons with time.129,169,170 Although traditionally
believed to be a model of infectious insult, a recently
developed PD animal model uses a systemic LPS admin-
istration, and shows that a single pro-inﬂammatory stim-
ulus can persistently activate microglia to cause neuron
death.156 Speciﬁcally, we have recently shown that sys-
temic LPS administration activates cells in the liver to
produce TNF-, which is distributed in the blood and
transferred to the brain through TNF- receptors to in-
duce the synthesis of additional TNF- and other pro-
inﬂammatory factors, creating a persistent and self-pro-
FIG. 1. Reactive microgliosis drives chronic neuron damage. Both stimulation of microglia with pro-inﬂammatory triggers (e.g.,
lipopolysaccharide [LPS]) and direct neuron damage (e.g., glutamate excitability) result in microglial activation causing the release of
neurotoxic factors, such as interleukin-1beta (IL-1), nitric oxide (NO), tumor necrosis factor-alpha (TNF-	), peroxynitrite (NOO-),
superoxide (O2
●), and hydrogen peroxide (H2O2). Subsequently, after damage with either a pro-inﬂammatory trigger or a direct
neurotoxin, the neuron releases microglial activators (soluble neuron-injury signals), such as  calpain, MMP3, 	-synuclein, and
neuromelanin, which activate microglial cells and propagate the cycle. This self-perpetuating cycle of neurotoxicity is known as reactive
microgliosis. LPS  lipopolysaccharide; MMP3  matrix metalloproteinase 3; MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
MPP  1-methyl-4-phenylpyridinium ion; 6-OHDA  6-hydroxydopamine; PGE2  prostaglandin E2; PM  particulate matter. This
ﬁgure was slightly modiﬁed from Block and Hong (2007)1.
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pelling neuro-inﬂammation that induces delayed and
progressive loss of DA neurons in the SN of adult ani-
mals.156 This work is the ﬁrst to support that a single
pro-inﬂammatory stimulus (whether pathogen or envi-
ronmental in origin) in the adult animal can cause pro-
gressive neuron damage later in life, suggesting a wide
therapeutic window for the effective use of anti-inﬂam-
matory therapy in neurodegenerative disease.
However, earlier reports have already shown that ex-
posure to LPS early in life can induce and enhance DA
neuron damage later in life. Studies show that during
critical periods of embryonic development (embryonic
day 10.5), maternal exposure to low concentrations of
LPS in mice impacts microglial activation and DA neu-
ron survival in offspring that persists into adult-
hood.170,171 Interestingly, LPS has been implicated in the
potential etiology of sporadic PD through sepsis and
early life exposure during pregnancy.169,172,173 Further-
more, diagnosed symptoms of PD, brain inﬂammation,
and damage to the SN have been described in a patient
who had received accidental systemic administration of
LPS.174 However, the most important implication of
these ﬁndings is that not only can microglia induce neu-
ron damage, but microglia can become persistently acti-
vated to produce continuous and uncontrolled neurotox-
icity that fails to resolve long after the instigating
stimulus has dissipated.
Priming: Lowering the threshold to initiate
neurotoxicity
The phenomenon of microglial priming offers valuable
insight into why microglia continue to respond to addi-
tional stimuli in the chronic cycle of neuro-inﬂammation
(FIG. 1). In the case of priming, microglia are not just
exhibiting an enhanced toxic microglial response.
Rather, in the case of priming, the microglial phenotype
shifts, in which a much lower stimulus is needed to exact
a toxic microglial response, which enhances the proba-
bility that the chronic cycle of toxic reactive microgliosis
will continue.
Systemic LPS has been widely explored for the ability
to amplify ongoing neuropathology in adults. Systemic
LPS administration has been shown to enhance prion-
induced cognitive deﬁcits, neuroinﬂammation, and neu-
ropathology.175 Furthermore, systemic neonatal expo-
sure to LPS is shown to signiﬁcantly amplify neuronal
death associated with ischemic insult.176 Finally, immu-
nological perturbation during critical periods of develop-
ment170 or aging177 and sentience,178 can prime micro-
glia, in which additional stimuli results in an exaggerated
and prolonged pro-inﬂammatory response that enhances
neuron damage.
By altering concentrations of intracellular ROS and
consequent redox-signaling, NADPH oxidase is reported
to prime the microglial response to further insult. Trig-
gers of microglia activation, such as rotenone55 and neu-
ronal death,179 are shown to prime microglia through
NADPH oxidase and result in synergistic microglial ac-
tivation, which is associated with neurotoxicity on addi-
tional insult with LPS. This has particular importance,
given that a multiple hit hypothesis180 has been proposed
as a potential mechanism through which environmental
toxicants induce neurodegenerative disease during an in
individual’s lifetime and may provide signiﬁcant insight
into the progressive nature of neuroinﬂammation.
CONCLUSIONS AND IMPLICATIONS
Microglia can be continuously activated to produce
toxic factors (cytokines and reactive oxygen species) by
either single or chronic exposure to disease proteins,
environmental toxins, cytokines, and neuronal damage
(reactive microgliosis), resulting in the progressive loss
of neurons with time, a fundamental component of neu-
rodegenerative disease. Recent work suggests that DA
neurons may be inherently vulnerable to reactive micro-
gliosis, providing much needed insight into the progres-
sive nature of PD. Current research also suggests that
redox signaling in microglia may be a critical mechanism
of chronic neuro-inﬂammation that propagates the mi-
croglial pro-inﬂammatory response through ampliﬁca-
tion of cytokine production and lowering of the stimulus
threshold to cause a neurotoxic toxic response. Future
research will need to focus on why the microglial re-
sponse fails to resolve when compared with the periph-
eral immune system, the mechanisms through which
ROS is signaling toxic microglial activation, and to har-
ness this information for the identiﬁcation of novel ther-
apeutic approaches.
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